Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, September 14, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.

These annual PhRMA resources share wide-ranging data points and updates on advances in treatment, research and development, market dynamics, cost sharing trends, medicine spending trends, outcomes and savings and the industry’s economic impact.

Other must-know industry facts include:

  • New medicines are making strides in reducing disease morbidity and mortality.
  • 74 percent of all drugs in clinical development are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease.
  • The biopharmaceutical industry’s average return on equity is 16.2 percent, similar to other industries including trucking, software and construction supplies.
  • Negotiated savings on brand prescriptions are often not shared with patients who are increasingly being asked to pay more out of pocket.
  • Spending on brand prescription medicines only accounts for 7 percent of total annual healthcare spending.
  • 5 percent of the population accounts for 50 percent of US health care spending.
  • The biopharmaceutical industry accounts for 1 out of every 6 dollars spent on domestic R&D by US businesses.

 

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.